Clinical Trial

The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is an investigator-initiated trial to evaluate the safety and efficacy of anti- CD19-CAR-T cells in the relapse or refractory autoimmune diseases.
Trial Details
NCT Number NCT06420154
Lead Sponsor First Affiliated Hospital of Wenzhou Medical University
Collaborators: Shanghai First Song Therapeutics Co., Ltd
Conditions Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy, ANCA Associated Vasculitis, Antiphospholipid Syndrome
Enrollment 9 participants
Start Date 2024-05-27
Primary Completion 2027-05-27 (estimated)
Study Completion 2027-05-27 (estimated)
Updated on ClinicalTrials.gov 2024-05-17